AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 34052249 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance Exercise (RE) - three sets of eight repetitions, seven weight-lifting exercises
Number of subjects: 12
Study 34052249 — intervention group
Group type: COMPARATOR
Intervention: Control (CON) - 45-min no-exercise control
Number of subjects: 12
Study 36027311 — intervention group
Group type: EXPERIMENTAL
Intervention: High salt intake (HIS: 200 mmol/day of sodium tablets)
Number of subjects: 15
Study 36027311 — intervention group
Group type: COMPARATOR
Intervention: Low salt diet (LSD: 50 mmol/day)
Number of subjects: 15
Study 32505529 — intervention group
Group type: EXPERIMENTAL
Intervention: Piezoelectric (PE)
Number of subjects: 30
Study 32505529 — intervention group
Group type: COMPARATOR
Intervention: Conventional drills (CD)
Number of subjects: 30
Study 35718438 — intervention group
Group type: EXPERIMENTAL
Intervention: Zygomatic implants
Number of subjects: 0
Study 35718438 — intervention group
Group type: COMPARATOR
Intervention: All-on-Four concept
Number of subjects: 0
Study 34000130 — intervention group
Group type: EXPERIMENTAL
Intervention: Pain Frequency, Intensity, and Burden Scale (P-FIBS)
Number of subjects: 4923
Study 34000130 — intervention group
Group type: EXPERIMENTAL
Intervention: Pain
Number of subjects: 4923
Study 32827053 — intervention group
Group type: EXPERIMENTAL
Intervention: Dissection with LigaSure Impact™
Number of subjects: 102
Study 32827053 — intervention group
Group type: COMPARATOR
Intervention: Conventional dissection
Number of subjects: 102
Study 36056328 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-Code Pause (PCP)
Number of subjects: 655
Study 36056328 — intervention group
Group type: COMPARATOR
Intervention: Debriefing In Situ Conversation after Emergent Resuscitation Now (DISCERN)
Number of subjects: 655
Study 33077560 — intervention group
Group type: EXPERIMENTAL
Intervention: Care Group Intervention
Number of subjects: 0
Study 33401270 — intervention group
Group type: EXPERIMENTAL
Intervention: ENB plus CBCT
Number of subjects: 62
Study 33401270 — intervention group
Group type: COMPARATOR
Intervention: ENB alone
Number of subjects: 62
Study 32139188 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with contralateral OA
Number of subjects: 241
Study 32139188 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with contralateral THA in place
Number of subjects: 241
Study 32139188 — intervention group
Group type: EXPERIMENTAL
Intervention: Distance from the tip of the trochanter to the top of the femoral head
Number of subjects: 241
Study 32139188 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased age
Number of subjects: 241
Study 32139188 — intervention group
Group type: EXPERIMENTAL
Intervention: Female gender
Number of subjects: 241
Study 34363901 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 35671829 — intervention group
Group type: EXPERIMENTAL
Intervention: Crushed tablets of prasugrel
Number of subjects: 0
Study 35671829 — intervention group
Group type: COMPARATOR
Intervention: Integral tablets of prasugrel
Number of subjects: 0
Study 33740926 — intervention group
Group type: EXPERIMENTAL
Intervention: Avapritinib (300 mg or 400 mg)
Number of subjects: 75
Study 33740926 — intervention group
Group type: COMPARATOR
Intervention: Other tyrosine kinase inhibitors (TKIs)
Number of subjects: 75
Study 36047381 — intervention group
Group type: EXPERIMENTAL
Intervention: Empowering Community Pharmacists program
Number of subjects: 55
Study 34158310 — intervention group
Group type: EXPERIMENTAL
Intervention: Rounding checklist intervention
Number of subjects: 420
Study 36223849 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.19-mg fluocinolone acetonide (FAc) intravitreal implant
Number of subjects: 159
Study 33827306 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 µg Dex intrathecally
Number of subjects: 108
Study 33827306 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 µg sufentanil intrathecally
Number of subjects: 108
Study 33827306 — intervention group
Group type: COMPARATOR
Intervention: 1 mL saline (0.9%) intrathecally
Number of subjects: 108
Study 32223057 — intervention group
Group type: EXPERIMENTAL
Intervention: Western diet‐like high-carbohydrate (WDHC) meal
Number of subjects: 0
Study 32223057 — intervention group
Group type: EXPERIMENTAL
Intervention: Western diet‐like high-fat (WDHF) meal
Number of subjects: 0
Study 32223057 — intervention group
Group type: EXPERIMENTAL
Intervention: Mediterranean diet (MED) meal
Number of subjects: 0
Study 32223057 — intervention group
Group type: EXPERIMENTAL
Intervention: All meals
Number of subjects: 0
Study 36008060 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse-led coaching of self-care agency intervention during hospitalisation and home supervision after discharge
Number of subjects: 60
Study 36008060 — intervention group
Group type: COMPARATOR
Intervention: Control group received routine nursing during hospitalisation and conventional family care after discharge without regular supervision
Number of subjects: 60
Study 36008060 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse-led coaching of self-care agency intervention
Number of subjects: 60
Study 33685923 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight loss through referral to community weight-loss programmes
Number of subjects: 2041
Study 36398411 — intervention group
Group type: EXPERIMENTAL
Intervention: myAlgos full version
Number of subjects: 80
Study 36398411 — intervention group
Group type: COMPARATOR
Intervention: Control version
Number of subjects: 80
Study 32003800 — intervention group
Group type: EXPERIMENTAL
Intervention: Years of schooling (SD = 3.6 years)
Number of subjects: 54062
Study 32003800 — intervention group
Group type: EXPERIMENTAL
Intervention: Intelligence (SD = 15 points on intelligence test)
Number of subjects: 54062
Study 32003800 — intervention group
Group type: COMPARATOR
Intervention: Intelligence
Number of subjects: 54062
Study 32003800 — intervention group
Group type: COMPARATOR
Intervention: Educational attainment
Number of subjects: 54062
Study 34970912 — intervention group
Group type: EXPERIMENTAL
Intervention: Highest tertile of serum GDF‐15 levels
Number of subjects: 572
Study 34970912 — intervention group
Group type: EXPERIMENTAL
Intervention: Log-transformed GDF‐15 levels
Number of subjects: 572
Study 34970912 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum GDF‐15 levels
Number of subjects: 572
Study 33002924 — intervention group
Group type: EXPERIMENTAL
Intervention: Capnogram waveform-guided bronchial cuff inflation (capno group, n = 27)
Number of subjects: 64
Study 33002924 — intervention group
Group type: COMPARATOR
Intervention: Pressure-guided bronchial cuff inflation (pressure group, n = 29)
Number of subjects: 64
Study 32843240 — intervention group
Group type: EXPERIMENTAL
Intervention: Prolonged Exposure (PE) therapy delivered in person
Number of subjects: 136
Study 32843240 — intervention group
Group type: EXPERIMENTAL
Intervention: Prolonged Exposure (PE) therapy delivered via telemedicine
Number of subjects: 136
Study 35618557 — intervention group
Group type: EXPERIMENTAL
Intervention: BCG vaccination
Number of subjects: 52954
Study 35618557 — intervention group
Group type: EXPERIMENTAL
Intervention: DTP vaccination
Number of subjects: 52954
Study 33715477 — intervention group
Group type: EXPERIMENTAL
Intervention: Lateral wedge insoles (2, 4, 6, 8, or 10 degrees)
Number of subjects: 38
Study 33715477 — intervention group
Group type: COMPARATOR
Intervention: Neutral insoles (0 degrees)
Number of subjects: 38
Study 32093379 — intervention group
Group type: EXPERIMENTAL
Intervention: Resveratrol (manufacturer’s recommended dose)
Number of subjects: 12
Study 32093379 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 36460265 — intervention group
Group type: EXPERIMENTAL
Intervention: Incentives Arm
Number of subjects: 380
Study 36460265 — intervention group
Group type: EXPERIMENTAL
Intervention: Tailored Messages Arm
Number of subjects: 380
Study 36460265 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined Arm
Number of subjects: 380
Study 36460265 — intervention group
Group type: COMPARATOR
Intervention: Control Arm
Number of subjects: 380
Study 33442932 — intervention group
Group type: EXPERIMENTAL
Intervention: Transaortic (TAo) approach
Number of subjects: 282
Study 33442932 — intervention group
Group type: COMPARATOR
Intervention: Transapical (TA) approach
Number of subjects: 282
Study 33442932 — intervention group
Group type: EXPERIMENTAL
Intervention: New York Heart Association III–IV
Number of subjects: 282
Study 33442932 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic renal failure
Number of subjects: 282
Study 33442932 — intervention group
Group type: EXPERIMENTAL
Intervention: Previous transient ischemic attack/stroke
Number of subjects: 282
Study 33442932 — intervention group
Group type: EXPERIMENTAL
Intervention: Sapien-3 device
Number of subjects: 282
Study 35900311 — intervention group
Group type: EXPERIMENTAL
Intervention: GCS (Gemcitabine, Cisplatin plus S-1)
Number of subjects: 246
Study 35900311 — intervention group
Group type: COMPARATOR
Intervention: GC (Gemcitabine, Cisplatin)
Number of subjects: 246
Study 34332818 — intervention group
Group type: EXPERIMENTAL
Intervention: Pain management education (10 minutes of education and a pain management reference card)
Number of subjects: 174
Study 34332818 — intervention group
Group type: COMPARATOR
Intervention: Standard care (no additional education)
Number of subjects: 174
Study 34167897 — intervention group
Group type: EXPERIMENTAL
Intervention: 900 mg nolasiban
Number of subjects: 45
Study 34167897 — intervention group
Group type: EXPERIMENTAL
Intervention: 1800 mg nolasiban
Number of subjects: 45
Study 34167897 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 45
Study 32046991 — intervention group
Group type: EXPERIMENTAL
Intervention: Digitally assisted nursing observations
Number of subjects: 755
Study 35288393 — intervention group
Group type: EXPERIMENTAL
Intervention: Emicizumab (3 mg/kg once per week for the first 4 weeks, followed by 1.5 mg/kg once per week, 3 mg/kg once every 2 weeks, or 6 mg/kg once every 4 weeks)
Number of subjects: 20
Study 35288393 — intervention group
Group type: EXPERIMENTAL
Intervention: Emicizumab
Number of subjects: 20
Study 35084163 — intervention group
Group type: EXPERIMENTAL
Intervention: Maximal Vertical Jump (VJ)
Number of subjects: 69
Study 35084163 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple Jump Series (MJ)
Number of subjects: 69
Study 35084163 — intervention group
Group type: COMPARATOR
Intervention: Control (CON)
Number of subjects: 69
Study 33236208 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional TENS (high frequency and low intensity)
Number of subjects: 60
Study 33236208 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture-like TENS (low frequency and high intensity)
Number of subjects: 60
Study 33236208 — intervention group
Group type: COMPARATOR
Intervention: Sham TENS
Number of subjects: 60
Study 36355202 — intervention group
Group type: EXPERIMENTAL
Intervention: Deep breathing (Group D)
Number of subjects: 200
Study 36355202 — intervention group
Group type: COMPARATOR
Intervention: Control (Group C)
Number of subjects: 200
Study 33389422 — intervention group
Group type: EXPERIMENTAL
Intervention: Corneal collagen cross‐linking treatment
Number of subjects: 54
Study 33389422 — intervention group
Group type: COMPARATOR
Intervention: Photorefractive keratectomy (control group)
Number of subjects: 54
Study 32299845 — intervention group
Group type: EXPERIMENTAL
Intervention: Riociguat 0.5 mg to 2.5 mg orally three times daily (n=60)
Number of subjects: 121
Study 32299845 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n=61)
Number of subjects: 121
Study 32299845 — intervention group
Group type: EXPERIMENTAL
Intervention: Riociguat
Number of subjects: 121
Study 32299845 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 121
Study 33845623 — intervention group
Group type: EXPERIMENTAL
Intervention: HA+ Zweymuller-type hip stem
Number of subjects: 51
Study 33845623 — intervention group
Group type: COMPARATOR
Intervention: HA− Zweymuller-type hip stem
Number of subjects: 51
Study 33845623 — intervention group
Group type: EXPERIMENTAL
Intervention: HA+ and HA− groups
Number of subjects: 51
Study 34429138 — intervention group
Group type: EXPERIMENTAL
Intervention: Incentive spirometry (IS) performed before surgery
Number of subjects: 80
Study 34429138 — intervention group
Group type: COMPARATOR
Intervention: Control group (no preoperative spirometry)
Number of subjects: 80
Study 33550242 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive fusion-targeted biopsy
Number of subjects: 602
Study 33550242 — intervention group
Group type: COMPARATOR
Intervention: Software-based fusion-targeted biopsy
Number of subjects: 602
Study 34089122 — intervention group
Group type: EXPERIMENTAL
Intervention: tolvaptan
Number of subjects: 0
Study 32130996 — intervention group
Group type: COMPARATOR
Intervention: Cancellous bone grafting (CBG)
Number of subjects: 20
Study 32130996 — intervention group
Group type: EXPERIMENTAL
Intervention: Vascularized medial femoral condyle (MFC) autografts
Number of subjects: 20
Study 35669656 — intervention group
Group type: EXPERIMENTAL
Intervention: Scalpel treatment (group B)
Number of subjects: 78
Study 35669656 — intervention group
Group type: COMPARATOR
Intervention: Lateral crypt block treatment (group A)
Number of subjects: 78
Study 35669656 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 78
Study 32641220 — intervention group
Group type: EXPERIMENTAL
Intervention: Caloric restriction (CR) for 16 weeks
Number of subjects: 20
Study 32641220 — intervention group
Group type: COMPARATOR
Intervention: Control diet for 16 weeks
Number of subjects: 20
Study 32067873 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrated collaborative care intervention
Number of subjects: 409
Study 36319521 — intervention group
Group type: EXPERIMENTAL
Intervention: Virtual Reality application for 10 minutes
Number of subjects: 86
Study 36319521 — intervention group
Group type: COMPARATOR
Intervention: Routine preoperative procedure
Number of subjects: 86
Study 34333030 — intervention group
Group type: EXPERIMENTAL
Intervention: RBM20 variants
Number of subjects: 793
Study 34333030 — intervention group
Group type: EXPERIMENTAL
Intervention: RBM20 heterozygotes
Number of subjects: 793
Study 34333030 — intervention group
Group type: EXPERIMENTAL
Intervention: RBM20 expression in the left ventricle
Number of subjects: 793
Study 32618539 — intervention group
Group type: EXPERIMENTAL
Intervention: Spanish version of the Internet Gaming Disorder Scale - Short Form (IGDS9-SF)
Number of subjects: 2173
Study 35582124 — intervention group
Group type: EXPERIMENTAL
Intervention: BNT162b2/BNT162b2
Number of subjects: 390
Study 35582124 — intervention group
Group type: EXPERIMENTAL
Intervention: BNT162b2/mRNA‐1273
Number of subjects: 390
Study 35582124 — intervention group
Group type: EXPERIMENTAL
Intervention: mRNA‐1273/mRNA‐1273
Number of subjects: 390
Study 35582124 — intervention group
Group type: EXPERIMENTAL
Intervention: mRNA‐1273/BNT162b2
Number of subjects: 390
Study 35582124 — intervention group
Group type: COMPARATOR
Intervention: mRNA‐1273
Number of subjects: 390
Study 32285486 — intervention group
Group type: EXPERIMENTAL
Intervention: Pressure injury prevention program
Number of subjects: 1015
Study 32285486 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 1015
Study 35902888 — intervention group
Group type: EXPERIMENTAL
Intervention: Substance Use Treatment and Recovery Team (START) intervention
Number of subjects: 0
Study 35902888 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 0
Study 32940731 — intervention group
Group type: EXPERIMENTAL
Intervention: Phase 3 Oxford UKR bearings
Number of subjects: 40
Study 32940731 — intervention group
Group type: EXPERIMENTAL
Intervention: Bearings that did not overhang the tibia
Number of subjects: 40
Study 32940731 — intervention group
Group type: EXPERIMENTAL
Intervention: Increasing BMI
Number of subjects: 40
Study 32940731 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased area of overhang
Number of subjects: 40
Study 32940731 — intervention group
Group type: EXPERIMENTAL
Intervention: Amount of medial overhang
Number of subjects: 40
Study 32940731 — intervention group
Group type: EXPERIMENTAL
Intervention: Distance between the bearing and tibial wall
Number of subjects: 40
Study 35974292 — intervention group
Group type: EXPERIMENTAL
Intervention: AEON ™ Endostapler (Lexington Medical) LLES
Number of subjects: 60
Study 35974292 — intervention group
Group type: COMPARATOR
Intervention: Medtronic Endo GIA™ Tri‐Staple technology (MTS)
Number of subjects: 60
Study 34281590 — intervention group
Group type: EXPERIMENTAL
Intervention: semaglutide 1.0 mg
Number of subjects: 30
Study 34281590 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 30
Study 35131124 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivational Interviewing (MI) plus HealthCall
Number of subjects: 114
Study 35131124 — intervention group
Group type: EXPERIMENTAL
Intervention: NIAAA Clinician's Guide (CG) plus HealthCall
Number of subjects: 114
Study 35131124 — intervention group
Group type: COMPARATOR
Intervention: CG-only
Number of subjects: 114
Study 35131124 — intervention group
Group type: EXPERIMENTAL
Intervention: CG + HealthCall
Number of subjects: 114
Study 33757520 — intervention group
Group type: EXPERIMENTAL
Intervention: BDP/FF/G (beclometasone dipropionate 100 µg, formoterol fumarate 6 µg, glycopyrronium 10 µg) via pressurised metered-dose inhaler, two puffs twice-daily for 24 weeks
Number of subjects: 708
Study 33757520 — intervention group
Group type: COMPARATOR
Intervention: BUD/FF (budesonide 160 µg, formoterol fumarate 4.5 µg) via dry-powder inhaler, two puffs twice-daily for 24 weeks
Number of subjects: 708
Study 32118385 — intervention group
Group type: EXPERIMENTAL
Intervention: Whey protein (WP)
Number of subjects: 30
Study 32118385 — intervention group
Group type: EXPERIMENTAL
Intervention: Leucine (LEU)
Number of subjects: 30
Study 32118385 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PLA)
Number of subjects: 30
Study 35152706 — intervention group
Group type: EXPERIMENTAL
Intervention: Pilates with elastic resistance (PAG)
Number of subjects: 22
Study 35152706 — intervention group
Group type: COMPARATOR
Intervention: Pilates without elastic resistance (PG)
Number of subjects: 22
Study 33825828 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical timolol maleate solution, 0.5%, applied twice daily for 24 weeks
Number of subjects: 69
Study 33825828 — intervention group
Group type: COMPARATOR
Intervention: Placebo applied twice daily for 24 weeks
Number of subjects: 69
Study 33825828 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical timolol maleate solution, 0.5%
Number of subjects: 69
Study 32737862 — intervention group
Group type: EXPERIMENTAL
Intervention: Virtual game training
Number of subjects: 26
Study 32737862 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 26
Study 33328284 — intervention group
Group type: EXPERIMENTAL
Intervention: Combo (50% basal rate reduction set at exercise onset with carbohydrate intake of 0.3 g/kg/h)
Number of subjects: 15
Study 33328284 — intervention group
Group type: EXPERIMENTAL
Intervention: CHO-only (usual basal rate with carbohydrate intake of 0.3 g/kg/h)
Number of subjects: 15
Study 33328284 — intervention group
Group type: EXPERIMENTAL
Intervention: −90min50%BRR (50% basal rate reduction set 90 min pre-exercise)
Number of subjects: 15
Study 33328284 — intervention group
Group type: EXPERIMENTAL
Intervention: −90min50%BRR
Number of subjects: 15
Study 33171431 — intervention group
Group type: EXPERIMENTAL
Intervention: Expressive writing intervention (4-day writing program adapted from Pennebaker and Beall, 1986)
Number of subjects: 154
Study 33171431 — intervention group
Group type: COMPARATOR
Intervention: Active control group (writing about untherapeutic topics)
Number of subjects: 154
Study 35666856 — intervention group
Group type: EXPERIMENTAL
Intervention: Goat milk based infant formula (GMF)
Number of subjects: 218
Study 35666856 — intervention group
Group type: COMPARATOR
Intervention: Cow milk formula (CMF)
Number of subjects: 218
Study 35666856 — intervention group
Group type: EXPERIMENTAL
Intervention: Breast fed (BF)
Number of subjects: 218
Study 32895369 — intervention group
Group type: EXPERIMENTAL
Intervention: JNJ-61393215 (90 mg)
Number of subjects: 0
Study 32895369 — intervention group
Group type: EXPERIMENTAL
Intervention: JNJ-61393215 (dose-dependent)
Number of subjects: 0
Study 32895369 — intervention group
Group type: COMPARATOR
Intervention: Control (Alprazolam)
Number of subjects: 0
Study 33603142 — intervention group
Group type: EXPERIMENTAL
Intervention: Sorafenib
Number of subjects: 267
Study 33603142 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 267
Study 35765169 — intervention group
Group type: EXPERIMENTAL
Intervention: low‐intensity exercise with BFR during rest intervals (rBFR)
Number of subjects: 10
Study 35765169 — intervention group
Group type: EXPERIMENTAL
Intervention: low‐intensity exercise only (EO)
Number of subjects: 10
Study 35765169 — intervention group
Group type: COMPARATOR
Intervention: low‐intensity exercise with BFR during exercise (eBFR)
Number of subjects: 10
Study 33813359 — intervention group
Group type: EXPERIMENTAL
Intervention: levodopa + donepezil (5 mg)
Number of subjects: 20
Study 33813359 — intervention group
Group type: COMPARATOR
Intervention: levodopa + placebo
Number of subjects: 20
Study 35168011 — intervention group
Group type: EXPERIMENTAL
Intervention: Values intervention
Number of subjects: 895
Study 35168011 — intervention group
Group type: EXPERIMENTAL
Intervention: Growth intervention
Number of subjects: 895
Study 35168011 — intervention group
Group type: COMPARATOR
Intervention: Study-skills control
Number of subjects: 895
Study 33478571 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture therapy (penetration needling of Hand‐Yangming meridian, PNHM) for 16 weeks
Number of subjects: 60
Study 33478571 — intervention group
Group type: COMPARATOR
Intervention: Observation period for 16 weeks followed by 16 weeks of compensation PNHM therapy
Number of subjects: 60
Study 33478571 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture therapy (PNHM)
Number of subjects: 60
Study 32259412 — intervention group
Group type: EXPERIMENTAL
Intervention: Laser and chemical intervention
Number of subjects: 24
Study 32259412 — intervention group
Group type: COMPARATOR
Intervention: Chemical intervention alone
Number of subjects: 24
Study 35072287 — intervention group
Group type: EXPERIMENTAL
Intervention: Filgotinib 200 mg once daily
Number of subjects: 0
Study 35072287 — intervention group
Group type: EXPERIMENTAL
Intervention: Filgotinib and GS-829845
Number of subjects: 0
Study 34383006 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypofractionated image-guided radiotherapy (IGRT) (60 Gy in 15 fractions)
Number of subjects: 96
Study 34383006 — intervention group
Group type: COMPARATOR
Intervention: Conventional fractionated radiotherapy (CFRT) (60 Gy in 30 fractions)
Number of subjects: 96